Dyne Therapeutics Announces Key Leadership Appointments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Coursera plans layoffs after Udemy merger, estimates $8M-$11M in costs
Oppenheimer Reiterates Outperform Rating on Dyne Therapeutics (DYN)
September 3, 2024 11:45 AM EDTOppenheimer analyst Francois Brisebois reiterated an Outperform rating and $55.00 price target on Dyne Therapeutics (NASDAQ: DYN).
The analyst comments "DYN reported new clinical data from its P1/2 DYNE-251 for DMD dose optimization studies. In addition to dose-dependent PMO delivery to muscle and exon... More
